Related Experiment Video
Updated: Jun 26, 2026

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
Published on: September 20, 2018
[Castleman's disease: presentation of an atypical case]
J Rodríguez Carrasco1, C E Fernández Marín, C López Peña
1Unidad de Gestión Clínica de Pediatría, Hospital Universitario San Cecilio, Granada, España. joserodriguezcarrasco@yahoo.es
Castleman disease, a rare lymphoproliferative disorder, presents in localized or multicentric forms. This report details a pediatric case of localized Castleman disease, highlighting successful surgical management and long-term outcomes.
Area of Science:
- Pediatric Oncology
- Hematology
- Pathology
Background:
- Castleman disease is a rare lymphoproliferative disorder of unknown etiology.
- It typically affects young adults but can occur in children, presenting as localized or multicentric forms.
- Histopathological subtypes include hyaline-vascular and plasma-cell variants, correlating with clinical presentation and prognosis.
Observation:
- This article presents a case of localized Castleman disease in a 3-year-old girl.
- The patient presented with a solitary mediastinal mass, characteristic of the localized form.
- The child remained asymptomatic for two years post-diagnosis and treatment.
Findings:
- Localized Castleman disease, particularly the hyaline-vascular type, is often successfully treated with surgical resection.
- The multicentric form presents a greater therapeutic challenge with varied treatment strategies yielding limited success.
- Accurate histopathological diagnosis is crucial for determining the appropriate management and predicting prognosis.
Implications:
- Castleman disease should be considered in the differential diagnosis of pediatric lymphoproliferative disorders.
- Early diagnosis and surgical intervention for localized Castleman disease can lead to favorable long-term outcomes.
- Further research into the etiology and effective treatments for multicentric Castleman disease is warranted.
Related Concept Videos
Type I Diabetes III: Clinical Manifestations
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Hyperglycemia
Diabetic Ketoacidosis l: Introduction
Diabetes: Symptoms, Diagnosis, and Complications
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes: